Advertisement
Novartis AG has agreed to buy Ebewe Pharma’s injectables unit for 1.2 billion US dollars (925 million euros) in an all-cash transaction that will add generic cancer drugs to the Swiss company’s offerings. The takeover excludes Ebewe Pharma’s neurological products business, Basel-based Novartis said in a statement on Wednesday, May 20, 2009.
Advertisement
Advertisement